MB0151
/ Mainline Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
May 22, 2025
Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors
(clinicaltrials.gov)
- P1/2 | N=156 | Recruiting | Sponsor: Mainline Biosciences (Shanghai) Co., Ltd | Not yet recruiting ➔ Recruiting
Enrollment open • Breast Cancer • Endocrine Cancer • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor • Triple Negative Breast Cancer
February 21, 2025
Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects with Advanced Solid Tumors Expressing Somatostatin Receptors
(clinicaltrials.gov)
- P1/2 | N=156 | Not yet recruiting | Sponsor: Mainline Biosciences (Shanghai) Co., Ltd
New P1/2 trial • Breast Cancer • Endocrine Cancer • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor • Triple Negative Breast Cancer
1 to 2
Of
2
Go to page
1